SCHEMBL3869064

SCHEMBL3869064

NC(=O)Nc1cc(Cl)ccc1OCC(=O)NC1CC2CCC(C1)N2Cc1ccc(F)cc1

nearest known ligand 0.55

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
CCR1 P32246 4/20 0.55
FPR3 P25089 1/20 0.55
GPR65 Q8IYL9 1/20 0.55
GPR35 Q9HC97 1/20 0.55
MAPT P10636 1/20 0.47
SMN1; SMN2 Q16637 2/20 0.46
NPC1 O15118 2/20 0.46
RAB9A P51151 1/20 0.46
MCHR1 Q99705 1/20 0.45
MEN1 O00255 1/20 0.44
KMT2A Q03164 1/20 0.44
OPRK1 P41145 1/20 0.44
DRD3 P35462 1/20 0.43
LMNA P02545 1/20 0.43
HPGD P15428 1/20 0.43
CXCR6 O00574 1/20 0.43
CCR3 P51677 2/20 0.42
CYP2D6 P10635 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3869061 1.00 CCR1 (0.55) CCR1FPR3GPR65GPR35MAPT
SCHEMBL3868695 0.95 CCR1 (0.51) CCR1FPR3GPR65GPR35MAPT
SCHEMBL3868699 0.95 CCR1 (0.51) CCR1FPR3GPR65GPR35MAPT
SCHEMBL3869170 0.95 CCR1 (0.48) CCR1FPR3GPR65GPR35MAPT
SCHEMBL3869555 0.95 CCR1 (0.48) CCR1FPR3GPR65GPR35MAPT
SCHEMBL3869168 0.95 CCR1 (0.48) CCR1FPR3GPR65GPR35MAPT
SCHEMBL13853100 0.92 MCHR1 (0.54) CCR1FPR3GPR65GPR35MAPT
SCHEMBL4669557 0.90 CCR1 (0.45) CCR1FPR3GPR65GPR35MAPT
SCHEMBL4669555 0.90 CCR1 (0.45) CCR1FPR3GPR65GPR35MAPT
SCHEMBL4668374 0.90 NPC1 (0.47) CCR1FPR3GPR65GPR35MAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1891064-B1 N-AMIDE DERIVATIVES OF 8-AZABICYCLO[3.2.1]OCT-3-YL AS CCR1 ANTAGONISTS ALMIRALL SA (ES) 2009-09-02 EP claimed
US-20090130090-A1 N-amide Derivatives of 8-Azabicyclo[3.2.1]OCT-3-YL AS CCR1 Antagonists LABORATORIOS ALMIRALL, S.A. (ES) 2009-05-21 US claimed
EP-1891064-A1 N-AMIDE DERIVATIVES OF 8-AZABICYCLO[3.2.1]OCT-3-YL AS CCR1 ANTAGONISTS Laboratorios Almirall, S.A. (ES) 2008-02-27 EP claimed
WO-2006133802-A1 N-AMIDE DERIVATIVES OF 8-AZABICYCLO[3.2.1]OCT-3-YL AS CCR1 ANTAGONISTS LABORATORIOS ALMIRALL, S.A. (ES) 2006-12-21 WO claimed
EP-1891064-B1 N-AMIDE DERIVATIVES OF 8-AZABICYCLO[3.2.1]OCT-3-YL AS CCR1 ANTAGONISTS ALMIRALL SA (ES) 2009-09-02 EP disclosed
US-20090130090-A1 N-amide Derivatives of 8-Azabicyclo[3.2.1]OCT-3-YL AS CCR1 Antagonists LABORATORIOS ALMIRALL, S.A. (ES) 2009-05-21 US disclosed
EP-1891064-A1 N-AMIDE DERIVATIVES OF 8-AZABICYCLO[3.2.1]OCT-3-YL AS CCR1 ANTAGONISTS Laboratorios Almirall, S.A. (ES) 2008-02-27 EP disclosed
WO-2006133802-A1 N-AMIDE DERIVATIVES OF 8-AZABICYCLO[3.2.1]OCT-3-YL AS CCR1 ANTAGONISTS LABORATORIOS ALMIRALL, S.A. (ES) 2006-12-21 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090130090-A1 N-amide Derivatives of 8-Azabicyclo[3.2.1]OCT-3-YL AS CCR1 Antagonists CCR1, CCR3, CCR8 CCR1 1/4885FPR3 45/4885GPR65 130/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.